Avantor price to book ratio AVTR
Market value divided by the book value of the company's net assets, since 2019.
- Today, Nov 2, 2026
- 1.9×
- 7-year median
- 3.1×
- Against its 7-year history
- 21st
- percentile: 0 is its lowest day, 100 its highest
- 7-year range
- 0.9× to 8.6×
- Peer median
- 4.3×
Avantor's price to book ratio is 1.9× as of Nov 2, 2026.
That is below its 7-year median of 3.1×, lower than on 79% of days in the last 7 years.
Over that time it ranged from 0.9× in Mar 2026 to 8.6× in Sep 2021.
The median for 10 diagnostics and research stocks of a similar size is 4.3×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.9× | 0.9× | 2.1× |
| 2025 | 1.4× | 1.2× | 2.7× |
| 2024 | 2.6× | 2.5× | 3.4× |
| 2023 | 3.0× | 2.4× | 3.5× |
| 2022 | 3.1× | 2.8× | 5.6× |
| 2021 | 6.3× | 5.6× | 8.6× |
| 2020 | 6.4× | 2.4× | 6.4× |
| 2019 | 4.4× | 3.3× | 4.4× |
Against its peers
Companies in Medical - Diagnostics & Research nearest Avantor's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| AVTRAvantor | 1.9× |
| BIOBio-Rad Laboratories | 1.4× |
| CAICaris Life Sciences | 15.3× |
| RVTYRevvity | 2.3× |
| LNTHLantheus | 5.0× |
| MEDPMedpace | 41.7× |
| BLLNBillionToOne | 9.7× |
| CDNACareDx | 9.7× |
| DGXQuest Diagnostics | 3.6× |
| VCYTVeracyte | 2.8× |
| LHLabcorp | 3.4× |
| Peer median | 4.3× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Avantor
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.